Trial Profile
Evaluation of the Efficacy of Sunitinib in Patients With Recurrent Ovarian Clear Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Adenocarcinoma; Ovarian cancer
- Focus Therapeutic Use
- 17 Jul 2018 Status changed from recruiting to completed.
- 10 Apr 2013 New trial record